FindTrial
Sign In

Develop a computer based model that identifies novel drug or drug combinations for Early T precursor (ETP) type acute lymphoblastic leukemia a type of blood cancer.

Tata Precision Oncology Program - Precision ETP-ALL Study - POP ETP-ALL study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/02/011823
Enrollment
48
Registered
2018-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- T-cell acute lymphoblastic leukemia (T-ALL)

Interventions

Intervention1: Not Applicable: Not Applicable Control Intervention1: Not Applicable: Not Applicable

Sponsors

Tata Memorial Hospital
Lead Sponsor
Not Any
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Samples from patients diagnosed with ETP-ALL as defined by flow cytometry evidence of lymphoblasts expressing absence of CD1a and CD8, weak CD5 expression, and the expression of one or more myeloid or stem cell-associated markers

Exclusion criteria

Exclusion criteria: Not Applicable

Design outcomes

Primary

MeasureTime frame
This study will help elucidate the biology of ETP-ALL as well as the computational modeling will help selecting the novel treatment options for ETP-ALL. This tailor- made therapy has a potential to improve outcomes in ETP-ALLTimepoint: single—

Secondary

MeasureTime frame
Not AnyTimepoint: Not Any—

Countries

India

Contacts

Public ContactDr Manju Sengar

Tata Memorial Center, Parel, Mumbai

manju.sengar@gmail.com0224177211

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026